Amoeba SA (ALMIB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Amoeba SA (ALMIB) has a cash flow conversion efficiency ratio of 0.644x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-3.45 Million ≈ $-4.04 Million USD) by net assets (€-5.36 Million ≈ $-6.27 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See ALMIB defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Amoeba SA - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Amoeba SA's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Amoeba SA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Amoeba SA ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hindustan Media Ventures Limited
NSE:HMVL
|
0.012x |
|
TETHYS PETROLEUM LTD
F:TP21
|
0.112x |
|
Akme Fintrade India Ltd
NSE:AFIL
|
-0.209x |
|
Ramssol Group Bhd
KLSE:0236
|
0.028x |
|
Cumberland Pharmaceuticals Inc
NASDAQ:CPIX
|
0.018x |
|
Vow ASA
OL:VOW
|
0.300x |
|
Clime Capital Ltd
AU:CAM
|
-0.045x |
|
International Media Acquisition Corp
NASDAQ:IMAQ
|
0.023x |
Annual Cash Flow Conversion Efficiency for Amoeba SA (2012–2025)
The table below shows the annual cash flow conversion efficiency of Amoeba SA from 2012 to 2025. For the full company profile with market capitalisation and key ratios, see how much is Amoeba SA worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €-5.36 Million ≈ $-6.27 Million |
€-6.13 Million ≈ $-7.16 Million |
1.143x | +182.19% |
| 2024-12-31 | €-10.41 Million ≈ $-12.17 Million |
€-4.22 Million ≈ $-4.93 Million |
0.405x | -75.44% |
| 2023-12-31 | €-3.94 Million ≈ $-4.61 Million |
€-6.50 Million ≈ $-7.60 Million |
1.649x | +349.19% |
| 2022-12-31 | €8.16 Million ≈ $9.54 Million |
€-5.40 Million ≈ $-6.32 Million |
-0.662x | +97.77% |
| 2021-12-31 | €198.68K ≈ $232.28K |
€-5.90 Million ≈ $-6.90 Million |
-29.704x | -1727.93% |
| 2020-12-31 | €2.00 Million ≈ $2.34 Million |
€-3.25 Million ≈ $-3.80 Million |
-1.625x | -89.00% |
| 2019-12-31 | €4.23 Million ≈ $4.94 Million |
€-3.64 Million ≈ $-4.25 Million |
-0.860x | +12.73% |
| 2018-12-31 | €5.41K ≈ $6.33K |
€-5.33K ≈ $-6.23K |
-0.985x | -142.87% |
| 2017-12-31 | €12.52K ≈ $14.64K |
€-5.08K ≈ $-5.94K |
-0.406x | -32.43% |
| 2016-12-31 | €18.63K ≈ $21.78K |
€-5.71K ≈ $-6.67K |
-0.306x | +22.04% |
| 2015-12-31 | €10.60K ≈ $12.39K |
€-4.16K ≈ $-4.87K |
-0.393x | +7.81% |
| 2014-12-31 | €2.80 Million ≈ $3.27 Million |
€-1.19 Million ≈ $-1.39 Million |
-0.426x | -136.98% |
| 2013-12-31 | €433.99K ≈ $507.38K |
€500.21K ≈ $584.79K |
1.153x | +771.59% |
| 2012-12-31 | €947.20K ≈ $1.11 Million |
€-162.56K ≈ $-190.04K |
-0.172x | -- |
About Amoeba SA
Amoéba S.A. develops biological products and services for the treatment of microbiological risk in the sectors of water, health, and plant protection in France. The company has developed technology to treat water, surfaces, and chronic wounds that uses the natural biocidal capacity of the living amoeba Willaertia magna C2c Maky; and agriculture biocontrol technology for the treatment of phytopath… Read more